´â·Ç¼¨ÈÄTOP ·Ç¼¨ÈÄ ¥Á¥ã¥Ã¥È ¾ðÊ󸡺÷ Wiki ¼­Åµ ÏÀʸ ¥ê¥ó¥¯½¸ ¥¢¥ó¥±¡¼¥È Êݸ± ½ñÀÒ ÍÑÉÊ
£Í£ù¥í¥°¥¤¥ó

ÏÀʸʣ¼Ì

    Á´Ê¸¸¡º÷
¾ÜºÙ¸¡º÷  
  ÏÀʸʣ¼Ì » ´â¤È²½³ØÎÅË¡ I » 31-07 ¥¢¥«¥¦¥ó¥È¾ðÊó  |  ¥«¡¼¥È¤ò¸«¤ë  |  ¥ì¥¸¤Ë¿Ê¤à   
ÉѽХ­¡¼¥ï¡¼¥É¤Çõ¤¹¤è¤¯»È¤ï¤ì¤ë¥­¡¼¥ï¡¼¥É¤¬ÅÐÏ¿¤µ¤ì¤Æ¤Þ¤¹
¥«¥Æ¥´¥ê¡¼
« ´â¤È²½³ØÎÅË¡ I»
  28-07
  28-09
  29-01
  29-02
  29-03
  29-05
  29-07
  29-08
  29-09
  29-10
  29-11
  30-01
  30-02
  30-03
  30-04
  30-05
  30-06
  30-07
  30-08
  30-09
  30-10
  30-11
  30-12
  30-13
  31-01
  31-02
  31-03
  31-04
  31-05
  31-06
31-07
  31-08
  31-09
  31-10
  31-11
  31-12
  31-13
½ÐÈÇÃÄÂÎÊ̤Çõ¤¹½ÐÈÇÊ̤Çõ¤¹
°ìÍ÷¤Çõ¤¹ °ìÍ÷ɽ¼¨¤Çõ¤¹
¶È̳¡¦ÄêµÙ
ÀÖ¤ÎÆü¤ÏȯÁ÷¤ò¤ªµÙ¤ß¤µ¤»¤Æ¤¤¤¿¤À¤­¤Þ¤¹¡£
2008ǯ12·î
Æü ·î ²Ð ¿å ÌÚ ¶â ÅÚ
¡¡ 1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31 ¡¡ ¡¡ ¡¡
¡¡
¥¤¥ó¥Õ¥©¥á¡¼¥·¥ç¥ó
¥Ë¥å¡¼¥¹
¤´ÍøÍÑÊýË¡
¸Ä¿Í¾ðÊóÊݸîÊý¿Ë
Áí³Ûɽ¼¨¤Ë¤Ä¤¤¤Æ
ÆÃÄ꾦¼è°úË¡¤Îɽ¼¨
¤è¤¯¤¢¤ë¼ÁÌä
¡¡¡¡¡ú²Á³Ê¤Ï¡©
¡¡¡¡¡ú»Ùʧ¤¤¤Ï¡©
¡¡¡¡¡úǼ´ü¤Ï¡©
¤ªÌ䤤¹ç¤ï¤»
¥µ¥Ý¡¼¥È·Ç¼¨ÈÄ

¥«¥Æ¥´¥êʬÎà ¤³¤ÎÃÄÂΤÎÏÀʸ

¤³¤Î¥«¥Æ¥´¥ê¤ÎRSS2.0


 ¿·Ãå½ç+   Ž×ŽÝŽ·ŽÝޏŽÞ 
 
ProteasomeÁ˳²ºÞ

  ¢£....¡¡ ¡¡1.³«È¯.Îò»Ë.¥³¥ó¥»¥×¥È¡¡ ¡¡2.ºîÍѵ¡½ø.ɸŪ¡¡ ¡¡3.Bortezomib°Ê³°.²½¹çʪ¡¡ ­µ......²½³ØÎÅË¡ºÞ.ʬ»ÒɸŪÌôºÞÂÑÀ­.....¸ú²Ì¡¡ ...

  ¢£ºâÃÄË¡¿Í´â¸¦µæ²ñÉí°É±¡¡¦²½³ØÎÅË¡²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° ProteasomeÁ˳²ºÞ ¤ò¿½¹þ¤à 
 
¼ðáç¥Þ¡¼¥«¡¼¤ÎÎ×¾²Åª°ÕµÁ

  ¢£Î×¾²¸¡ºº¡¢¿ÇÃÇ.ÍÑ..¼ðáç¥Þ¡¼¥«¡¼¡¡ ....¡¡ ­µ.¥Ï¥¤¥ê¥¹¥¯¾ÉÎã..¼ðáç¥Þ¡¼¥«¡¼¡¡ ­¶.´â¿ÇÃÇ..ÁÈ.¹ç..¡¡ ­·.¡´ïÊÌ.´ÕÊÌ¿ÇÃÇ.¥â¥Ë¥¿¥ê¥ó¥°¡¡ ­¸.¼ðáç¥Þ¡¼¥«¡¼...

  ¢£°ñ¾ë¸©Î©Ãæ±ûɱ¡¡¦°ñ¾ë¸©Ãϰ褬¤ó¥»¥ó¥¿¡¼...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° ¼ðáç¥Þ¡¼¥«¡¼¤ÎÎ×¾²Åª°ÕµÁ ¤ò¿½¹þ¤à 
 
Sentinel Node Navigation Surgery¤ÏÇÙ´â¼ê½Ñ¤Î¥ê¥ó¥ÑÀá³ÇÀ¶¤ò¤É¤³¤Þ¤Ç¾Êά¤Ç¤­¤ë¤«?

  ¢£¥»¥ó¥Á¥Í¥ë¥ê¥ó¥ÑÀá.¸¦µæºÇÁ°Àþ¡¡ ....¡¡ ­µ.ÊýË¡¡¡101Îã ­¶.·ë²Ì¡¡ ­·.¹Í»¡¡¡ ·ë¸ì¡¡...

  ¢£ÅìµþÅÔºÑÀ¸²ñÃæ±ûɱ¡¡¦¸ÆµÛ´ï³°²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° Sentinel Node Navigation Surgery¤ÏÇÙ´â¼ê½Ñ¤Î¥ê¥ó¥ÑÀá³ÇÀ¶¤ò¤É¤³¤Þ¤Ç¾Êά¤Ç¤­¤ë¤«? ¤ò¿½¹þ¤à 
 
Etoposide,Ara-C¾¯ÎÌ»ý³ÅÀÅ©ÎÅË¡¤ËMitoxantrone¤ò²Ã¤¨¤¿MEtAÎÅË¡¤Ë¤è¤ê´²²ò¤òÆÀ¤¿De Novo AML with Trilineage Myelodysplasia(AML/TMDS)¤Î5¾ÉÎã

  ¢£½ï¸À¡¡ ­µ.ÂоÝ.ÊýË¡¡¡ ­¶.¾ÉÎã¡¡50ºÐ½÷À­¡¡ÈùÇ®¡¢Æ°Ø©¡¢Â©ÀÚ..ÉÏ·ì¾É¾õ¡¢²¼Î¡¡¡5ǯ°Ê¾å̵ÉÂÀ¸Â¸Ãæ ¡¡¡¡¡¡¡¡¡¡¡¡44ºÐÃËÀ­¡¡²¼ÂÜÉâ¼ð¡¢·ì±Õ¸¡ºº..°Ê¾å»ØÅ¦¡¡¡¡ ¡¡¡¡¡¡¡¡...

  ¢£»ÔΩºæÉ±¡¡¦·ì±ÕÆâ²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° Etoposide,Ara-C¾¯ÎÌ»ý³ÅÀÅ©ÎÅË¡¤ËMitoxantrone¤ò²Ã¤¨¤¿MEtAÎÅË¡¤Ë¤è¤ê´²²ò¤òÆÀ¤¿De Novo AML with Trilineage Myelodysplasia(AML/TMDS)¤Î5¾ÉÎã ¤ò¿½¹þ¤à 
 
³°¼ªÆ»Á£ÍÍǹ˦´â¤Î¿ȯÀ­ÇÙž°Ü¤ËTS-1¤¬ÁÕ¸ú¤·¤¿1Îã

  ¢£....¡¡ ­µ.¾ÉÎã¡¡67ºÐÃËÀ­¡¡º¸¼ªÏ³¡¢...¡¡ ­¶.¹Í»¡¡¡...

  ¢£*1·ò¹¯Êݸ±ÌÄÌçɱ¡¡¦¼ªÉ¡°ö¹¢²Ê, *2·ò¹¯Êݸ±ÌÄÌçɱ¡¡¦³°...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú¡ù

º£¤¹¤° ³°¼ªÆ»Á£ÍÍǹ˦´â¤Î¿ȯÀ­ÇÙž°Ü¤ËTS-1¤¬ÁÕ¸ú¤·¤¿1Îã ¤ò¿½¹þ¤à 
 
TamoxifenÅêÍ¿¤Ë¤è¤ê¹â¥È¥ê¥°¥ê¥»¥é¥¤¥É·ì¾É¤òÍ褷¤¿Æý´â½Ñ¸å¤Î3Îã

  ¢£....¡¡ ­µ.¾ÉÎã¡¡60ºÐ½÷À­¡¡41ºÐ½÷À­¡¡78ºÐ½÷À­¡¡ ­¶.¹Í»¡¡¡ ·ë¸ì¡¡...

  ¢£»³ÍüÂç³Ø°å³ØÉô¡¦ÂèÆó³°²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° TamoxifenÅêÍ¿¤Ë¤è¤ê¹â¥È¥ê¥°¥ê¥»¥é¥¤¥É·ì¾É¤òÍ褷¤¿Æý´â½Ñ¸å¤Î3Îã ¤ò¿½¹þ¤à 
 
l-Leucovorin/5-FluorouracilÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿´âÀ­Ê¢Ëì±ê¤òȼ¤¦²¼¹Ô·ëIJ´â¤Î1Îã

  ¢£....¡¡ ­µ.ÅêÍ¿ÊýË¡¡¡ ­¶.¾ÉÎã.¼£Îŷвᡡ65ºÐÃËÀ­¡¡ÓÒÅÇ¡¡Ê¢Éô¶ÛËþ¡¡¾åÊ¢ÉôÄË¡¡¸ÆµÛº¤Æñ¡¡ ­·.¹Í»¡¡¡...

  ¢£*1»°±É²ñ¥Ä¥«¥¶¥­É±¡¡¦³°²Ê, *2Âçºå»ÔΩÂç³ØÂç³Ø±¡°å³Ø¸¦...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° l-Leucovorin/5-FluorouracilÊ»ÍÑÎÅË¡¤¬Ãø¸ú¤·¤¿´âÀ­Ê¢Ëì±ê¤òȼ¤¦²¼¹Ô·ëIJ´â¤Î1Îã ¤ò¿½¹þ¤à 
 
ÂçIJ´â½Ñ¸å3ÆüÌܤ˵޷ã¤ËÁýÂ礷´ÎÉÔÁ´¤¬´í¤Ö¤Þ¤ì¤¿Â¿È¯À­´Îž°Ü¤ËÂФ·5-Fluorouracil´ÎưÃíÎÅË¡¤¬ÁÕ¸ú¤·¤¿1Îã

  ¢£....¡¡ ­µ.¾ÉÎã¡¡68ºÐÃËÀ­¡¡Ê¢ÉôËÄËþ´¶¡¡±¦Â¦Ê¢ÉôÄË¡¡ ­¶.¹Í»¡¡¡...

  ¢£*1»°Âô»ÔΩ»°Âôɱ¡¡¦³°²Ê, *2»°Âô»ÔΩ»°Âôɱ¡¡¦Æâ²Ê ²½...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° ÂçIJ´â½Ñ¸å3ÆüÌܤ˵޷ã¤ËÁýÂ礷´ÎÉÔÁ´¤¬´í¤Ö¤Þ¤ì¤¿Â¿È¯À­´Îž°Ü¤ËÂФ·5-Fluorouracil´ÎưÃíÎÅË¡¤¬ÁÕ¸ú¤·¤¿1Îã ¤ò¿½¹þ¤à 
 
½ÑÁ°²½³ØÎÅË¡¤È¤·¤Æl-Leucovorin+5-FluorouracilÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÂçIJ´â¤Î1¾ÉÎã

  ¢£....¡¡ ­µ.¾ÉÎã¡¡45ºÐ½÷À­¡¡¸¡¿Ç..ÊØÀø·ìÍÛÀ­.»ØÅ¦¡¡ ­¶.¹Í»¡¡¡...

  ¢£»³·Á¸©Î©¿·¾±É±¡¡¦³°²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ù

º£¤¹¤° ½ÑÁ°²½³ØÎÅË¡¤È¤·¤Æl-Leucovorin+5-FluorouracilÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ÂçIJ´â¤Î1¾ÉÎã ¤ò¿½¹þ¤à 
 
TS-1+PaclitaxelÊ»ÍÑÎÅË¡¤Ë¤Æ´âÀ­Ê¢¿å¤¬¾Ã¼º¤·¤¿¥¹¥­¥ë¥¹·¿°ß´â¤Î1Îã

  ¢£....¡¡ ­µ.¾ÉÎã¡¡56ºÐ½÷À­¡¡¿´ãÝÉôÄË¡¡ ­¶.¹Í»¡¡¡...

  ¢£ºÑÀ¸²ñ¿áÅÄɱ¡¡¦¾Ã²½´ï¡¦°ìÈ̳°²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú¡ú

º£¤¹¤° TS-1+PaclitaxelÊ»ÍÑÎÅË¡¤Ë¤Æ´âÀ­Ê¢¿å¤¬¾Ã¼º¤·¤¿¥¹¥­¥ë¥¹·¿°ß´â¤Î1Îã ¤ò¿½¹þ¤à 
 
TS-1¼£ÎÅÄñ¹³À­ºÆÈ¯°ß´â¤ËÂФ·TS-1+CPT-11Ê»ÍÑÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿1Îã

  ¢£....¡¡ ­µ.¾ÉÎã¡¡71ºÐ¡¡ÃËÀ­¡¡¿©ÍßÉÔ¿¶¡¡º¸ðôÉô¼ðáî¡¡ ­¶.¹Í»¡...

  ¢£ÀÐÀîÅçÇÅËá½Å¹©¶È·ò¹¯Êݸ±ÁȹçÇÅËáɱ¡¡¦³°²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° TS-1¼£ÎÅÄñ¹³À­ºÆÈ¯°ß´â¤ËÂФ·TS-1+CPT-11Ê»ÍÑÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿1Îã ¤ò¿½¹þ¤à 
 
°ß´â¤Î¿ȯÀ­´Îž°Ü¤ËTS-1ÆâÉþ¤ÈMMCÀÅÃí¤¬Ãø¸ú¤·¤¿1Îã

  ¢£....¡¡ ­µ.¾ÉÎã¡¡49ºÐ¡¡ÃËÀ­¡¡¸¡¿Ç.ÉÏ·ì»ØÅ¦..¡¡ ­¶.¹Í»¡¡¡...

  ¢£Âù¶¨°å²ÊÂç³Ø¡¦Âè°ì³°²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° °ß´â¤Î¿ȯÀ­´Îž°Ü¤ËTS-1ÆâÉþ¤ÈMMCÀÅÃí¤¬Ãø¸ú¤·¤¿1Îã ¤ò¿½¹þ¤à 
 
TS-1/CDDPÊ»ÍÑÎÅË¡¤Ë¤ÆÌçÌ®Æâ¼ðáçÀò¤¬¾Ã¼º¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã

  ¢£....¡¡ ­µ.¾ÉÎã¡¡71ºÐÃËÀ­¡¡2·¿°ß´â ÂνŸº¾¯¡¢¥¿¡¼¥ëÊØ¡¡ ­¶.Î×¾²·Ð²á¡¡ ­·.¹Í»¡¡¡...

  ¢£±Ê¼÷Áí¹çɱ¡¡¦³°²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° TS-1/CDDPÊ»ÍÑÎÅË¡¤Ë¤ÆÌçÌ®Æâ¼ðáçÀò¤¬¾Ã¼º¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¤ò¿½¹þ¤à 
 
TS-1/CDDPÊ»ÍÑÊü¼ÍÀþÎÅË¡¤Ë¤Æ´°¼£¤·¤¿ðôÉô¡¦¶»Éô¾åÉô¿Ê¹Ô¿©Æ»´â¤Î1Îã

  ¢£....¡¡ ­µ.¾ÉÎã¡¡52ºÐÃËÀ­¡¡Óë²¼¾ã³²¡¡¿´¶Ú¹¼ºÉ¡¡ ­¶.¹Í»¡¡¡...

  ¢£*1¹ñΩ̾¸Å²°É±¡¡¦¾Ã²½´ï²Ê, *2¹ñΩ̾¸Å²°É±¡¡¦Êü¼ÍÀþ²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° TS-1/CDDPÊ»ÍÑÊü¼ÍÀþÎÅË¡¤Ë¤Æ´°¼£¤·¤¿ðôÉô¡¦¶»Éô¾åÉô¿Ê¹Ô¿©Æ»´â¤Î1Îã ¤ò¿½¹þ¤à 
 
ͽËÉŪÁ´Ç¾¾È¼Í¸å¤ÎǾž°Ü¤ËNogitecan Hydrochloride(Topotecan)¤¬Í­¸ú¤Ç¤¢¤Ã¤¿ÇÙ¾®ºÙ˦´â¤Î1Îã

  ¢£....¡¡ ­µ.¾ÉÎã¡¡55ºÐ½÷À­¡¡±¦ÇÙ¾åÍÕ¼ðáî¡¡ ­¶.·Ð²á¡¡ ­·.¹Í»¡¡¡...

  ¢£*1µþÅÔÂè°ìÀÖ½½»úɱ¡¡¦¸ÆµÛ´ï²Ê, *2µþÅÔÉÜΩ°å²ÊÂç³ØÂç³Ø...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú¡ù

º£¤¹¤° ͽËÉŪÁ´Ç¾¾È¼Í¸å¤ÎǾž°Ü¤ËNogitecan Hydrochloride(Topotecan)¤¬Í­¸ú¤Ç¤¢¤Ã¤¿ÇÙ¾®ºÙ˦´â¤Î1Îã ¤ò¿½¹þ¤à 
 
Á°Î©Á£´â¤Ë¤ª¤±¤ëCepharanthin¤ÎÊü¼ÍÀþ¤ÎÀµ¾ïÁÈ¿¥¾ã³²ÍÞÀ©¸ú²Ì

  ¢£....¡¡ ­µ.Âоݡ¦ÊýË¡¡¡97Îã Á°Î©Á£´âÊü¼ÍÀþ¼£ÎÅ´µ¼Ô ­¶.·ë²Ì¡¡ ­·.¹Í»¡¡¡...

  ¢£»º¶È°å²ÊÂç³Ø¡¦Êü¼ÍÀþ²Ê³Ø¶µ¼¼...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° Á°Î©Á£´â¤Ë¤ª¤±¤ëCepharanthin¤ÎÊü¼ÍÀþ¤ÎÀµ¾ïÁÈ¿¥¾ã³²ÍÞÀ©¸ú²Ì ¤ò¿½¹þ¤à 
 
Cisplatin and Gemcitabine in Patients with Metastatic Cervical Cancer

  ¢£Introduction ­µ.Patients amd methods 1.Eligibility 2.Pretreatment evaluation ...

  ¢£Division of Therapeutic Radiol...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° Cisplatin and Gemcitabine in Patients with Metastatic Cervical Cancer ¤ò¿½¹þ¤à 
 
ÂçIJ´âÁÈ¿¥ÃæDPD¡¦OPRT³èÀ­¤è¤ê¤ß¤¿ÂçIJ´â¤ËÂФ¹¤ë²½³ØÎÅË¡

  ¢£....¡¡ ­µ.ÂоÝ.ÊýË¡¡¡ ­¶.·ë²Ì¡¡ÂçIJ´â46Îã(·ëIJ´â28ÎãľIJ´â18Îã) ¡¡1.´âÉô¡¦Àµ¾ïÉô.DPD³èÀ­¡¦OPRT³èÀ­.Èæ³Ó¡¡ ¡¡2.DPD³èÀ­.Î×¾²ÉÂÍý³ØÅª°ø»Ò....

  ¢£Âçºå»ÔΩÂç³ØÂç³Ø±¡°å³Ø¸¦µæ²Ê¡¦¾Ã²½´ï³°²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° ÂçIJ´âÁÈ¿¥ÃæDPD¡¦OPRT³èÀ­¤è¤ê¤ß¤¿ÂçIJ´â¤ËÂФ¹¤ë²½³ØÎÅË¡ ¤ò¿½¹þ¤à 
 
¹âÅٿʹ԰ߴâ¤ËÂФ¹¤ëLow-Dose TS-1+CDDPÎÅË¡¸å¤ÎSecond-Line Therapy¤Î¸¡Æ¤

  ¢£....¡¡ ­µ.ÂоÝ.ÊýË¡¡¡ ¡¡1.Âоݡ¡16Îã ¡¡2.ÌôºÞÅêÍ¿ÊýË¡¡¡ ¡¡3.¸ú²ÌȽÄê¡¡ ­¶.·ë²Ì¡¡ ­·.¹Í»¡¡¡...

  ¢£·Ã¼÷Áí¹çɱ¡³°²Ê¡¦°ßIJ²Ê...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ù

º£¤¹¤° ¹âÅٿʹ԰ߴâ¤ËÂФ¹¤ëLow-Dose TS-1+CDDPÎÅË¡¸å¤ÎSecond-Line Therapy¤Î¸¡Æ¤ ¤ò¿½¹þ¤à 
 
ƬðôÉô´â¤Ë¤ª¤±¤ëCepharanthin¤ÎÊü¼ÍÀþ¸ý¹Ð´¥Áç¾ÉÍÞÀ©¸ú²Ì

  ¢£¥Ð¥¤¥ª¥Þ¡¼¥«¡¼.°ÕµÁ.ÌäÂêÅÀ¡¡ ....¡¡ ­µ.Âоݡ¦ÊýË¡¡¡ ­¶.·ë²Ì¡¡ ­·.¹Í»¡¡¡...

  ¢£»º¶È°å²ÊÂç³Ø¡¦Êü¼ÍÀþ²Ê³Ø¶µ¼¼...  ¢£630±ß(ÀÇÈ´600±ß)  
 ¡ú¡ú¡ú

º£¤¹¤° ƬðôÉô´â¤Ë¤ª¤±¤ëCepharanthin¤ÎÊü¼ÍÀþ¸ý¹Ð´¥Áç¾ÉÍÞÀ©¸ú²Ì ¤ò¿½¹þ¤à 
 1 - 20 ÈÖÌܤòɽ¼¨ (26 ¤¢¤ëÏÀʸ¤Î¤¦¤Á)   ¥Ú¡¼¥¸:  1  2  [¼¡¥Ú¡¼¥¸ >>]  
°ÊÁ°¤´ÍøÍѤµ¤ì¤¿Êý
E-Mail ¥¢¥É¥ì¥¹:
¥Ñ¥¹¥ï¡¼¥É:
¥Ñ¥¹¥ï¡¼¥Éʶ¼º
´ØÏ¢¤Î¤¢¤ë½ñÀÒ
¥¢¥¯¥»¥¹¥é¥ó¥¯
¡ú¥ª¥¹¥¹¥á


¤¬¤ó²½³ØÎÅË¡¥ì¥¸¥á¥ó
¥ì¥Ó¥å¡¼

¤Ò¤È¤Þ¤º¡¢¤É¤Î¥ì¥Ù¥ë¤Þ¤Ç¼£¸³¤¬¿Ê¤ó¤Ç¤¤¤ë¤Î¤«¤Î»²¹Í¤Ë¤Ê¤ê¤Þ¤· ..
5ÅÀÃæ¤Î 3ÅÀ!
¡Ú¹­¹ð¡Û

¡Ú·ÀÌó¥Ñ¡¼¥È¥Ê¡¼¡Û
ÆüËÜÃøºî½ÐÈǸ¢´ÉÍý¥·¥¹¥Æ¥àÍÍ
       TOP ¥¢¥«¥¦¥ó¥È¾ðÊó  |  ¥«¡¼¥È¤ò¸«¤ë  |  ¥ì¥¸¤Ë¿Ê¤à